ATOS 📈 Atossa Genetics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04962H5063
ATOS: Breast Cancer Treatment, Oral Endoxifen, Immunotherapy
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Web URL: https://www.atossatherapeutics.com
Additional Sources for ATOS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ATOS Stock Overview
| Market Cap in USD | 135m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2012-11-08 |
ATOS Stock Ratings
| Growth 5y | -34.8% |
| Fundamental | -48.7% |
| Dividend | - |
| Rel. Strength Industry | -10.8 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 0.77 USD |
| Fair Price DCF | - |
ATOS Dividends
No Dividends PaidATOS Growth Ratios
| Growth Correlation 3m | -89.5% |
| Growth Correlation 12m | 10.8% |
| Growth Correlation 5y | -51.3% |
| CAGR 5y | -9.45% |
| CAGR/Mean DD 5y | -0.14 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | -45.70 |
| Beta | 2.05 |
| Volatility | 61.56% |
| Current Volume | 732.3k |
| Average Volume 20d | 984.1k |
What is the price of ATOS stocks?
As of January 10, 2025, the stock is trading at USD 0.92 with a total of 732,283 shares traded.
Over the past week, the price has changed by -3.69%, over one month by -26.02%, over three months by -33.95% and over the past year by +1.48%.
As of January 10, 2025, the stock is trading at USD 0.92 with a total of 732,283 shares traded.
Over the past week, the price has changed by -3.69%, over one month by -26.02%, over three months by -33.95% and over the past year by +1.48%.
Is Atossa Genetics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Atossa Genetics (NASDAQ:ATOS) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -48.74 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ATOS as of January 2025 is 0.77. This means that ATOS is currently overvalued and has a potential downside of -16.3%.
Probably not. Based on ValueRay Fundamental Analyses, Atossa Genetics (NASDAQ:ATOS) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -48.74 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ATOS as of January 2025 is 0.77. This means that ATOS is currently overvalued and has a potential downside of -16.3%.
Is ATOS a buy, sell or hold?
Atossa Genetics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ATOS.
Atossa Genetics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ATOS.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for ATOS stock price target?
According to ValueRays Forecast Model, ATOS Atossa Genetics will be worth about 0.9 in January 2026. The stock is currently trading at 0.92. This means that the stock has a potential downside of -4.35%.
According to ValueRays Forecast Model, ATOS Atossa Genetics will be worth about 0.9 in January 2026. The stock is currently trading at 0.92. This means that the stock has a potential downside of -4.35%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6 | 552.2% |
| Analysts Target Price | 4.8 | 425% |
| ValueRay Target Price | 0.9 | -4.3% |